

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|             |                        |   |                     |
|-------------|------------------------|---|---------------------|
| Applicants: | Albrecht et al.        | ) |                     |
|             |                        | ) |                     |
| Serial No.: | 09/748,642             | ) | Examiner: J. Shultz |
|             |                        | ) |                     |
| Filed:      | December 22, 2000      | ) | Art Unit: 1635      |
|             |                        | ) |                     |
| For:        | INHIBITION OF CELLULAR | ) |                     |
|             | PROTEASES              | ) |                     |
|             |                        | ) |                     |

---

**REQUEST FOR RECONSIDERATION****VIA EFS**

Commissioner for Patents  
 PO Box 1450  
 Alexandria, VA 22313-1450

Sir:

Applicants request reconsideration the October 5, 2006 office action relating to the above-identified patent application.

**REMARKS**

The rejection of claims 6, 7, 14 and 15 under 35 U.S.C. §112(first paragraph) for lack of enablement is respectfully traversed.

Attached hereto is a Declaration of Thomas Albrecht and Zhenping Chen Under 37 CFR 1.132 ("Declaration"). As shown in the Declaration, the claims of the present application are enabled.

In particular, calpain inhibitors E64D and Z-Leu-Leu-H are known to be cell permeable (Declaration ¶ 8). Online catalogs which offer calpain inhibitors E64D and Z-Leu-Leu-H for sale indicate that they are cell permeable (Declaration ¶ 9). Calpain inhibitors, such as E64D have been used successfully in animal models to decrease calpain activity